Edesa Biotech announced a net loss of $4.2 million for Q2 2026, reflecting increased R&D spending as it advances its Phase 2 vitiligo study and Phase 3 respiratory trials. The company is preparing for mid-2026 patient recruitment for its vitiligo drug EB06 and reported positive Phase 3 data for its respiratory drug paridiprubart. Despite higher operating costs, Edesa remains confident in its clinical progress and plans to continue developing treatments for immuno-inflammatory diseases. Cash and working capital stood at $10 million and $8.2 million respectively as of March 31, 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
